Research progress on the prevention of hepatocellular carcinoma recurrence after surgery
10.3760/cma.j.cn113884-20200525-00288
- VernacularTitle:肝细胞癌术后预防复发的研究进展
- Author:
Tao WEI
;
Feixiang WU
;
Lequn LI
;
Xiaobo WANG
- From:
Chinese Journal of Hepatobiliary Surgery
2021;27(4):316-320
- CountryChina
- Language:Chinese
-
Abstract:
Primary liver cancer is one of the most common malignant tumors in the world, and hepatocellular carcinoma accounts for the majority of liver cancer. Hepatectomy is one of the most important treatment methods, but the high postoperative recurrence rate is the leading cause of treatment failure, which seriously reduces the long-term survival rate and reduces quality of life. Therefore, preventing the recurrence of liver cancer is an important part of treatment. At present, there is no standard program for the treatment of hepatocellular carcinoma to prevent recurrence after surgery, most of the treatment programs include transarterial chemoembolization, antiviral therapy, traditional Chinese medicine treatment, targeted therapy, immunity therapy, etc., which has certain clinical significance in preventing recurrence. This paper reviewed the research progress on preventing recurrence of hepatocellular carcinoma after surgery, which may provide guidance for the clinical study.
